Diazoxide Suppression Test P&F Study

Part of paid clinical trials in New York, New York.

Sponsor
Columbia University
Study ID
NCT06606327
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Hyperinsulinemia
  • Insulin Resistance
  • Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Diazoxide, 3 mg/kg per dose — DRUG
    Insulin anti-secretagogue taken for 8 doses over 4 days

Study Details

The goal of this study is to learn about how the hormone insulin controls blood sugar. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. People with obesity and high insulin levels will receive eight doses of diazoxide, a drug that suppresses the pancreas's production of insulin, and will have their fasting blood sugar and insulin levels checked daily while taking the drug.

Key Dates

Start date
Oct 23, 2024
Status verified
Dec 2025
Primary completion
Nov 30, 2027
Completion
Jan 31, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Diazoxide
    Subjects will take diazoxide oral suspension at 3 mg/kg per dose for 4 days (total of 8 doses)

Primary Outcome Measure

Fasting plasma glucose [ Time Frame: Baseline and after 4 days of diazoxide treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Columbia University Irving Medical CenterNew YorkNew York10032
Joshua R Cook, MD, PhD
[email protected]
212-305-9336
[email protected]
Joshua R Cook, MD, PhD (PRINCIPAL_INVESTIGATOR)
Luca Sacchetta, MD (SUB_INVESTIGATOR)

Find similar trials in New York, NY

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Columbia University Irving Medical Center· New York, NY

Related Studies